Gilead Bets Big on Twice-Yearly HIV Preventive Yeztugo to Seize Market Leadership

Jul 02, 2025 14:09 CST Updated 14:09

Gilead Sciences

Innovative Drug Developer, Distributor

GSK

Pharmaceutical R&D Manufacturer

1. A New Chapter in HIV Prevention: One Injection Every Six Months

Gilead Sciences Challenges Market Dominance with Newly Approved Six-Month HIV Prevention Drug Yeztugo

Gilead Sciences' Total HIV Product Revenue Reaches $19.6 Billion in 2024, with Once-Daily Treatment Biktarvy Contributing $13.4 Billion, Followed by Preventive Drug Descovy at $2.1 Billion. However, the Emergence of Yeztugo Could Reshape the Market Landscape — Data Shows Current Adherence to Oral PrEP Medications is Only Around 50%, While Long-Acting Formulations Are Expected to Increase This Rate to Over 80%.

2. Triple Target Audience: From Stock Conversion to Global Expansion

Gilead CEO Daniel O’Day Outlines Three Key Focus Areas for Yeztugo at Goldman Sachs Conference:

Conversion of Existing Users: Targeting the 400,000 to 450,000 existing PrEP users in the U.S. A HIV specialist revealed to Mizuho analysts that the "vast majority" of their Apretude patients and the "majority" of oral medication users may switch to Yeztugo, with only about 10% likely to remain on oral options due to needle phobia.
Incremental Market Development: Covering 750,000 to 800,000 high-risk individuals in the U.S. who are not receiving preventive care. Current PrEP users are mostly men who have sex with men in large cities. Gilead plans to reach underserved groups, such as ethnic minorities and rural areas, through community education.
Global Layout: Replicating U.S. experience in overseas markets. O’Day pointed out that preventing one case of HIV can save $1.1 million in lifetime medical costs, a financial argument that will be key to persuading health departments of various countries to make purchases.

The progress of medical insurance coverage is a key variable. Gilead Sciences expects that Yeztugo will achieve 70%-75% payer coverage within six months of its launch, increasing to 90% by the end of the first year, laying the foundation for rapid scaling.

3. GSK's Counterattack: Apretude's Differentiated Defense

Facing the threat from Yeztugo, GSK's ViiV Healthcare did not back down. Sales of its bimonthly injectable Apretude surged 90% last year to $383 million. Company chairman David Redfern emphasized, "There is still significant unmet demand in the market, and the entry of new players will only help grow the overall pie."

GSK's Defense Strategy Focuses on Two Points:

Differentiation of Side Effects: Redfern pointed out that Yeztugo had a higher proportion of nodules at the injection site (abdomen), and users who are sensitive to body image may prefer Apretude;
Pipeline Iteration Preparation: Plan to launch a half-year PrEP drug between 2028-2030 to directly compete with Yeztugo, while advancing a combination of long-acting treatment drugs, aiming to capture more ground in the 90% share of the treatment market.

But industry insiders believe that GSK's counterattack pace is slightly lagging — its next-generation PrEP drug is 3-5 years behind Yeztugo, a window period that could allow Gilead Sciences to consolidate its first-mover advantage.

4. Behind the Market Game: Balancing Long-term Effectiveness and Fairness

The rise of Yeztugo reflects two major trends in HIV prevention and treatment: long-acting formulations becoming the mainstream of research and development, while equitable access to medication remains an unresolved challenge. Currently, PrEP coverage in the U.S. is less than 30%, with even lower accessibility in severely affected regions like Africa. Although Gilead Sciences has pledged to promote global availability, the pricing of the twice-yearly injection (expected to cost thousands of dollars per dose) could be a barrier.

Moreover, the direct showdown between the two long-acting injectables will test the logic behind the payers' choices. A health insurance plan director told reporters: "We focus more on overall cost-effectiveness — although Yeztugo’s six-month cycle reduces the number of administrations, the cost of managing nodule side effects may offset some of its advantages."

With the launch of Yeztugo, the "duel between two giants" in the HIV prevention market has officially begun. The ultimate winner of this competition will not only need a technological edge but also find the best balance between improving adherence, covering broader populations, and ensuring global accessibility. For the millions of high-risk individuals, the innovations brought about by this rivalry may well be the greatest blessing.

Reference Source:https://www.biospace.com/business/gilead-eyes-hiv-market-domination-with-twice-yearly-yeztugo-as-gsk-trails

Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming

All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and not of this site.